UNSPSC 51172122: Denaverine or denaverine hydrochloride

This classification denotes an anticholinergic agent with the molecular formulas C24H33NO3 and C24H33NO3.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers O14NF38MTL and 2AFK8FCD4R. European Medicines Agency schedules Denaverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06973MIG.

UNSPSC 51172122 Denaverine or denaverine hydrochloride, a Commodity code, covers pharmaceutical active ingredients and finished drug products supplied to state and local health and criminal justice agencies. Recent state and local opportunities under this code show demand for drug-testing services, generic pharmaceutical procurement, and direct-to-manufacturer pharmacy programs. Issuing bodies include county corrections departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across participating state agencies and local government facilities. The solicitations reveal procurement of specimen collection and drug testing services (including immunoassay screening and confirmatory testing by LC/MS/MS or GC/MS), generic pharmaceuticals and over-the-counter products distributed through authorized wholesalers, and exploratory contracting models for direct relationships between state pharmacy programs and manufacturers outside traditional pharmacy benefit manager channels.

Activity concentrates in Texas and Minnesota, with multistate reach through cooperative purchasing vehicles. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026 (due July 23, 2026) for offender specimen collection and drug testing services, covering approximately 25,031 annual tests across five-panel and six-panel screens with LC/MS/MS or GC/MS confirmation, estimated at $600,000 over two years with optional renewals through year five. The Texas Health and Human Services Commission posted RFI HHS0017013 on March 27, 2026 (response due April 3, 2026) seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program targeting self-insured employers and government health plans. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) through the Minnesota Multistate Cooperative Purchasing Alliance for generic pharmaceuticals and OTC products to participating state and local facilities, with awarded vendors effective July 1, 2026 and the contract term running through June 30, 2028. All proposals require documentation of FDA compliance, cGMP certification, or SAMHSA/state licensing where applicable.